Navigation Links
Darvone-Darvocet Failure to Warn Claims Reinstated against Generic Drug Maker Wright & Schulte LLC Report
Date:3/15/2013

Dayton, OH (PRWEB) March 15, 2013

Wright & Schulte LLC, an experienced drug injury law firm, reports that Judge Reeves reinstated failure to warn claims against aaiPharma after dismissing them last March. Judge Reeves centered his decision on a controversial 2011 ‘preemptive’ ruling by the U.S. Supreme Court that generic drug manufacturers are protected from failure to warn lawsuits because they are federally required to carry the same warning labels as their brand name counterparts. This High Court ruling allows generic drug manufacturers to avoid liability for dangerous side effects, even if the generic manufacturer knows about the dangers.

Judge Reeves also decided that his interpretation of the High Court ruling barred the plaintiffs charges of breach of implied warranty, negligent marketing, defective design, strict liability and negligent design as well, writing in his decision that generic drug makers have a ‘federal duty of sameness’ that requires generic drugs to made the same as the brand name version, which prevents them from being responsible for those charges. Judge Reeves made his ruling March 1, 2013, after the plaintiff was able to show that he consumed Darvocet while it was being manufactured by aaiPharma. (Darvocet, Darvon and Propoxyphene. Products Liability Litigation – MDL 2226)

Darvon Darvocet Multidistrict Litigation
In November 2010 the Propoxyphene painkillers Darvon and Darvocet and their generic counterparts were pulled from the market after studies found that when taken at normal dosages, the drugs were causing serious side effects in healthy people. These side effects include heart arrhythmia, heart attack and sudden death. (http://www.citizen.org/Document.Doc?id=29)

Hundreds of federally filed Darvon and Darvocet injury lawsuits were consolidated by the U.S. Judicial Panel for Multidistrict Litigation in June 2012 to the U.S. District Court for the Eastern District of Kentucky under Judge Reeves. Wright & Schulte LLC partner Richard Schulte is serving as Co-Lead Council in the MDL.

Darvocet Darvon Side Effects
The opioid Propoxyphene is sold as Darvon or when combined with acetaminophen as Darvocet. It first hit the market in 1957 and became a widely prescribed painkiller. While the drugs had been pulled from the European market in 2009, the U.S. Food and Drug Administration only required a stronger warning label. In 2010, with some 10 million users in the U.S. alone, the government agency issued a ban on the drugs after it found that recommended dosages given to healthy individuals increased the risks of:

  •      Suicide
  •     Overdose
  •     Heart attack
  •     Heart arrhythmia
  •     Sudden death

About Wright & Schulte LLC
Wright & Schulte LLC, an experienced drug injury law firm, is dedicated to the belief that America’s legal system should work for the people. Every day, the attorneys of Wright & Schulte LLC stand up for the rights of people who have been injured or wronged, and fight tirelessly to ensure that even the world’s most powerful corporations take responsibility for their actions. If you’ve been injured due to a harmful drug side effect, we urge you to contact Wright & Schulte LLC today through yourlegalhelp.com, or call 1-800-399-0795.

Contact:
Wright & Schulte LLC
812 East National Road
Vandalia, Ohio 45377
1-800-399-0795

Read the full story at http://www.prweb.com/releases/2013/3/prweb10521123.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Blood Test Plus Targeted Care May Stop Heart Failure Before It Starts
2. A Cheap, Old Heart Drug May Help Elderly Heart Failure Patients
3. Viagra, Aliskiren Not Helpful for Heart Failure After All: Studies
4. Common erectile dysfunction drug not helpful for heart failure patients, study finds
5. Certain Diabetes Medications May Lower Heart Failure Risk
6. Study: Diabetic medication may protect patients from developing heart failure
7. Researchers develop new tool to eliminate 30-day hospital readmissions in heart failure patients
8. Black Breast Cancer Survivors Face Higher Heart Failure Risk: Study
9. African-American breast cancer survivors face higher risk of heart failure
10. Electronic discharge tool reduces hospital readmissions in heart failure patients
11. Insomnia Might Boost Heart Failure Risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... Long Beach, CA (PRWEB) , ... June 25, 2016 , ... ... from UCLA with Magna Cum Laude and his M.D from the David Geffen School ... San Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of ... recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at Work ... Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... awareness about the dangers associated with chronic pain and the benefits of holistic treatments, ... for individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary ... Dallas that it will receive two significant new grants to support its work ... marked its 25th anniversary by recognizing patients, medical professionals and scientists for their ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 The Academy of ... recommendations that would allow biopharmaceutical companies to ... entities that make formulary and coverage decisions, a move ... of new medicines. The recommendations address restrictions ... appear on the drug label, a prohibition that hinders ...
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ... company developing innovative inhaled drugs, announced today that it ... Russell Investments reconstituted its comprehensive set of U.S. ... "This is an important milestone for Pulmatrix," said ... increase shareholder awareness of our progress in developing drugs ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who ... challenges of the current process. Many of them do not ... the technical difficulties and high laboratory costs involved. And those ... offer it at such a high cost that the majority ... Dr. Parsa Zadeh , founder of Dental ...
Breaking Medicine Technology: